Investment Pitches

Pitch Summary:
Distinguished by its proven antibody discovery engine that has yielded eight approved medicines, Genmab is approaching patent expirations for its flagship product, Darzalex, in the late 2020s and early 2030s. Investors routinely flee when a patent cliff looms, fixating on the certain loss of legacy revenue while discounting whatever might replace it. Genmab sits squarely in that sentiment trough. Today its shares trade for less than the value of already-approved drugs, implying the world-class pipeline and discovery engine are worth nothing. Meanwhile, a slate of late-stage assets and a growing roster of partnered drugs are only beginning to contribute revenue, with sales and royalties that extend well into the 2030s. Genmab’s R&D machine is still run by its scientist-founder, Dr Jan van de Winkel, whose more than two-decade tenure and sizeable equity stake have fostered disciplined capital allocation and scientific excellence. The company’s recent acquisition of ProfoundBio adds antibody-drug-conjugate technology that slots neatly into Genmab’s core expertise, expanding the opportunity set without stretching the balance sheet. Yet, the market still treats Genmab as a single-product story, allowing investors to buy the stock at a price that’s lower than the value of its commercialised drugs’ cash flows alone and get a world-class discovery platform for free.

BSD Analysis:
Genmab is evolving from royalty collector to full commercial biotech, with a pipeline of bispecifics and next-gen antibodies that give it real long-term upside. Royalty streams provide cushion while internal programs ramp. The balance sheet is pristine, margins are strong, and clinical execution has been consistently solid. Investors still price Genmab like a slow-growth Scandinavian pharma, not a global oncology innovator. Big catalysts from multiple trials provide meaningful convexity. The story isn’t flashy, but it’s durable. A European biotech powerhouse hiding behind conservative optics.

Pitch Summary:
This company stands at the forefront of RNA-interference (RNAi) therapeutics, a technology capable of silencing specific gene expressions and reducing harmful proteins. After decades of development, RNAi has proven safe and effective in treating serious diseases like Transthyretin amyloid cardiomyopathy (ATTR-CM). Each of Alnylam’s four marketed medicines and two partnered medicines were invented in-house—a remarkable R&D productivity streak highlighting its scientific prowess. Earlier this year Alnylam received regulatory approval for its next-generation ATTR-CM medicine, Amvuttra. We believe Amvuttra represents a best-in-class treatment that will significantly benefit patients. With the first commercial quarter results now in, Amvuttra has exceeded market expectations by a wide margin, validating our initial thesis. Alnylam’s management team, led by CEO Dr. Yvonne Greenstreet, continues to demonstrate both scientific rigour and strong commercial execution. This stronger-than-expected sales ramp puts Alnylam firmly on track to achieve profitability this year and strengthens its position among biotech giants like Vertex and Gilead.

BSD Analysis:
Alnylam continues to own the RNAi space with a pipeline and commercial portfolio that most biotech CEOs would kill for. Margins expand as revenue scales, and the platform’s optionality across cardiometabolic and rare diseases keeps widening. Partnerships provide non-dilutive funding and external validation. Bears gripe about valuation, but they underestimate the durability of Alnylam’s technology moat. The next wave of late-stage readouts will be decisive in proving RNAi can dominate multiple large indications. The company executes with discipline and consistency. A premium biotech compounder with real staying power.

Pitch Summary:
However, loans held on the balance sheet rose to nearly $1B, largely driven by $700M in R&D (Home and Auto) loans. CEO Dave Girouard called this a timing issue tied to new product lines, noting plans to move these loans off balance sheet by year-end. Wall Street was unimpressed, and the subsequent $600M convertible note raise did little to improve confidence in Upstart’s ability to sell these loans. We believe this is purely a timing issue, as both Auto and HELOC continue to scale rapidly, growing 6x and 9x YoY, respectively. Later in August, we identified a partnership between Upstart and Progressive that had yet to gain mainstream attention. Originally and quietly announced in 2019, the collaboration remains active today. Progressive periodically emails its customers offering personal loan options and those who click through are redirected directly to Upstart’s platform. This partnership gains synergy as Upstart begins to launch and scale new credit products (such as Auto and HELOC) enabling them to better serve more borrowers.

BSD Analysis:
Upstart is still swinging between brilliance and chaos — a company with real AI underwriting tech stuck in a credit market that refuses to cooperate. Loan buyers are picky, cost of capital is high, and funding inconsistency keeps throttling growth. Yet the model works when macro stabilizes, and the speed of conversion improvement during good quarters hints at massive torque. The market treats UPST like a failed idea, which creates an opportunity if macro tailwinds ever return. Execution must tighten, but the core thesis isn’t dead. UPST is volatility personified — and that’s exactly what gives it upside.

Pitch Summary:
In Q3 2025, Heartwood sold Shark Ninja (SN) and Academy Sports and Outdoors (ASO) to rotate into CoreWeave (CRWV). We had a very small position in Shark Ninja, at a substantial gain, and believed the opportunity costs was too great not to reallocate capital. In the case of ASO… We believe CoreWeave better fits these principles.

BSD Analysis:
CoreWeave is scaling faster than almost any infrastructure provider in the AI ecosystem, building GPU clusters that customers simply can’t source from legacy clouds. The company moves aggressively, iterating hardware partnerships, networking, and scheduling tech to deliver superior performance for specialized workloads. Demand from AI labs, VFX studios, and high-performance compute clients is exploding. CoreWeave is unprofitable — but that’s because it’s sprinting to capture a land grab where speed is everything. The strategic value of a GPU-optimized cloud cannot be overstated. If CoreWeave maintains momentum, it becomes one of the defining winners of the AI infrastructure era. A future IPO rocket.

Pitch Summary:
We rotated the small principal left from the sale into Nebius (NBIS) at a cost basis of $31.35, with shares currently trading for $121.80. The resulting 288% gain has not only fully offset our entire DNUT loss, but has generated incremental outperformance for the fund. This trade now stands as Heartwood’s best ever.

BSD Analysis:
Nebius is positioning itself as a specialized AI cloud platform at a moment when enterprises desperately want alternatives to hyperscaler lock-in. Its GPU-dense configurations and low-latency architecture give it real differentiation for training and inference workloads. Early customer momentum suggests the market is hungry for a more flexible high-performance compute provider. Revenue is still emerging, but the demand signal is real. The question isn’t whether the TAM is big — it’s whether Nebius can scale faster than competitors notice. If it executes, Nebius becomes a must-own asset in the AI infrastructure stack. A high-upside, early-stage cloud disruptor.

Pitch Summary:
In Q4 2024, Heartwood took a large stake in Uranium Energy Corporation (UEC) which was funded by our sale of Google. We believed that as the AI race accelerated, data center power constraints would become much more visible to the broader market. UEC, as an American uranium miner (u3o8 is the core ‘ingredient’ in nuclear energy), was perfectly positioned to benefit from this accelerated demand. While GOOGL shares have risen nearly 40% since our exit, our UEC position has appreciated over 130%, transforming it into Heartwood’s largest holding.

BSD Analysis:
UEC is a pure torque play on the West’s scramble for nuclear fuel independence, with strategic U.S.-based assets that position it perfectly as geopolitics tighten. The company isn’t the lowest-cost producer, but its footprint aligns with a government-backed reshoring wave that rewrites the economics of uranium supply. Physical uranium holdings add ballast and optionality. Volatility is part of the package — the stock overshoots in both directions. But if uranium enters a sustained deficit (and signs point that way), UEC’s leverage becomes a feature, not a bug. This is not a yield story — it’s a conviction bet on a multi-year nuclear renaissance. High torque, high upside.

Pitch Summary:
Shares of Grindr have entered into a steep decline over the quarter. The market now believes GRND faces increased competition, from a fast growing “orgy” dating app Sniffies, as well as overstated/inflated user metrics. While Grindr has addressed these concerns, ARPPU growth came in light during their most recent quarter and a short report was issued, adding steam to this narrative. We continue to believe Grindr is positioned well to become the social network for the LGBTQ+ community and we anticipate adding to our stake in Q3.

BSD Analysis:
Grindr’s engagement metrics are off the charts, giving it one of the stickiest user bases in social media — a rare advantage in a churn-heavy industry. The company is finally monetizing intelligently with tiered subscriptions and richer features that boost ARPU without hurting usage. Margins are exceptional for a company this size, but governance quirks keep institutions cautious. The core product is highly defensible — there is no meaningful competitor with its community depth or brand equity. Growth is lumpy, yet the long-term trajectory remains compelling. If management tightens execution and improves transparency, rerating follows quickly. GRND is one of the few niche social platforms with real pricing power.

Pitch Summary:
Our largest holding, Upstart, reported mixed Q2 2025 results, holding an increased position of loans on the balance sheet. This caused shares to fall nearly 20% following ER, as the market expected an ATM capital raise which was soon to follow. Additionally, in late September, BTIG, an investment management firm, published a report claiming Upstart delinquencies had risen rapidly, putting further pressure on shares. This report was factually inaccurate and we shall have more to say on it later in this letter.

Grindr’s shares declined sharply in Q3 2025 amid competition from emerging apps and a short report on user metrics. Maple Tree disputes these concerns, citing stable engagement and growth potential as the platform evolves into a social hub for the LGBTQ+ community. The fund expects ARPPU growth to recover and plans to add to its position as capital allows.

Maple Tree Capital remains long Upstart. We continue to believe the company’s fundamental improvements (a diversified product, borrower and funding base) coupled with their rapidly growing AI edge position then well to become the leading AI lending marketplace.

BSD Analysis:
Upstart keeps swinging at the same pitch — AI underwriting that outperforms FICO — but the macro backdrop has been unforgiving. Loan performance volatility and a skittish funding environment keep throttling growth. Even so, the tech has real potential: conversion improves when partners return, and Upstart’s models remain meaningfully smarter than traditional scoring. The market’s treating this like a broken idea, but the revenue torque could be explosive if credit normalizes. Execution still matters — one bad cohort spoils the narrative fast. High-risk, high-reward, and still deeply misunderstood. UPST is an option on a future where underwriting is automated.

Pitch Summary:
Warrior Met Coal is a leading metallurgical coal producer (coal used to steel production). Currently the bulk of HCC’s FCF is being invested in a capital project that will be concluding this year. Once the business winds down their investment period they will gush cash. In Q2 2025, Warrior Met Coal saw revenue down 30% year-over-year due to compressing met coal prices. Despite a 6% production increase and tight cost control, negative free cash flow of $57 million reflects heavy investment in the Blue Creek mine. Liquidity remains robust at $545 million. Management maintained its full-year guidance, emphasizing the strength of contracted sales, cost discipline, and continued advancement of the Blue Creek project amid market headwinds. HCC’s existing mines should generate $100-$350MM in annual free cash flow (assuming lower for longer met coal prices). Blue Creek development is wrapping up by the beginning of 2026 and at mid-cycle should generate $100-$500MM in additional free cash flow. The combined assets should generate $200MM-$850MM in free cashflow with non-heroic pricing and volume assumptions. This equates to ~$4-$16 in annual per share cash generation vs. a price of ~$64 or a 6-25% unlevered annual free-cashflow yield. 2026 should be a sea-change in their free-cash-flow generation.

BSD Analysis:
Warrior Met remains one of the highest-quality met-coal producers globally, with low-cost operations and long-life reserves leveraged directly to steelmaking demand. Cash flow remains robust even amid pricing volatility, enabling aggressive capital returns. Operational performance is consistent, and the Blue Creek project provides a major growth catalyst. Despite strong fundamentals, the stock trades at a steep discount due to cyclical fears. Warrior’s balance sheet strength and cost advantages make it one of the safest ways to own met-coal.

Pitch Summary:
Tidewater is a marine services firm that operates one of the world’s largest fleets of offshore support vessels (OSVs). They serve the energy industry by transporting crew and supplies, towing and anchoring drillships and supporting offshore construction projects. The long-term outlook for international and offshore markets is strong while the near-term is a little cloudier. As current resource plays (the Permian) slow down worldwide demand will continue to grow and require more oil. It is expected that offshore capital commitments will rebound in the next 1-2 years. What’s striking about this industry is the lack of investment in the OSV fleet. Since the GFC global shipyard capacity has shrunk by nearly 60%. In addition, newbuild investment is lacking as many banks have pulled back from lending. Over the next decade, as fleets age, the global OSV market is expected to shrink by ~40%. What this adds up to is a potential for large pricing moves, in our favor, coupled with high utilization. But we do not have to bank on that as they are currently generating $300MM+ in FCF vs. a $2.7bb market cap or an 11% yield. In a more normal environment, I’d expect them to generate 500mm-1bb which gets to ~20-35% yields. Importantly their share buybacks were historically limited by debt covenants. That debt has been paid off (they have minimal debt now) and they recently instituted a buyback plan for $500MM.

BSD Analysis:
Tidewater is benefitting from one of the strongest offshore cycles in a decade, with dayrates climbing and utilization tight across its modern vessel fleet. The industry’s multi-year underinvestment supports structurally higher pricing. Tidewater’s operational leverage is enormous, and cash generation is accelerating at an impressive clip. Despite the upcycle, the stock still trades below normalized mid-cycle earnings power. With demand for offshore services rising globally, TDW remains a high-torque energy-services compounder.

Pitch Summary:
Lanxess is a German specialty chemicals company that was originally spun off from Bayer 20 years ago. The management team has been focused on selling more cyclical and capital-intensive businesses and building out stickier/lower capital-intensive businesses. For example, “Mobility” (cyclical auto/tires) was ~40% of their business in 2016 and today is ~15%. Additionally, they’ve focused on growing their business in the US. For example, US business was ~15% of sales in 2016 and is approaching ~30% today. Over the last 3 years leverage reached ~5x debt/EBITDA. As they’ve sold off some of the cyclical businesses, they’ve reduced debt to ~3.4x as of now. This is still too high for this kind of business and management targets ~2.5x leverage and an investment grade credit rating. The core business should be able to generate ~200-250mm in free-cash flow in a more normalized environment which equates to an 11-14% free-cashflow yield. They’re currently experiencing weak end-market use and generating 130-160mm in cash, which equals a 7-9% yield. This leaves out a large source of value. LXS has a JV with a put right to their partner. This has 1BB Euro value to LXS (equity value + debt owed to LXS). They exercised their put right and are now waiting for their JV partner to respond with their intentions. In any event LXS will be receiving somewhere between 500mm-1bb euros. If we conservatively assume 500mm of a cash-inflow the business is currently generating a 10-12% yield and will generate 15-20% mid-cycle yield. Once the company delevers I anticipate they will buy in a lot of stock at these levels.

BSD Analysis:
Lanxess remains a restructuring and margin-repair story, with portfolio simplification and cost-cutting aimed at stabilizing earnings after years of chemical-sector volatility. Specialty additives and consumer protection provide higher-margin anchors, while weaker basic-chem segments are being addressed through partnerships and divestitures. Cash flow is improving as working capital normalizes. Sentiment is washed out, but the long-term strategy is credible. If management continues delivering on execution, Lanxess has meaningful rerating potential.

Pitch Summary:
Flagstar Financial is the former New York Community Bank (a mashup of Flagstar Bank, New York Community Bank and assets from Signature Bank). Like our SHORT investments in Silicon Valley Bank and First Republic, FLG had a hole in their balance sheet (from soured multifamily and office real estate vs. long-duration securities). That is where the similarities end. FLG raised over $1BB in additional capital, led by former Treasury Secretary Steven Mnuchin. They revamped the management team and brought in a superstar CEO in Joseph Otting. They have reviewed nearly all the loans on the books, sold off non-core assets, raising additional capital and are focused on delivering a narrowly focused, well-capitalized boring regional bank. In this case boring is good. Importantly, they have taken a conservative view of their loan book and a large credit reserve. This contrasts with several bank/private credit lenders we are short who have taken minimal reserves. Flagstar continued making progress in their turnaround in the 2nd quarter. Their losses are shrinking, and the balance sheet is getting more stabilized. They have been deliberately reducing their exposure to the riskier segments of the commercial real estate market. At quarter-end the bank was trading at ~65% of a conservatively marked balance sheet. This is in contrast with similar banks (who are NOT conservatively marked) trading at 140-160% of their tangible book value. FLG should complete working thru the bulk of their issues by the end of 2025 and approach “normal” during 2026. Given the conservative nature of the management team, I wouldn’t be surprised if it happened sooner. At these prices the downside seems minimal and could see this business up 50-150% over the next 1-3 years as it is more appropriately valued.

BSD Analysis:
Flagstar remains a well-positioned regional bank with strong mortgage servicing capabilities, diversified deposits, and improving credit quality. The merger with New York Community Bank expands its footprint and provides scale advantages across retail banking and MSRs. While interest-rate volatility creates earnings noise, core fundamentals are stable and integration synergies are underappreciated. The stock trades at a discount reflecting merger complexity rather than impaired economics. As normalization continues, Flagstar screens as an undervalued regional-bank value play.

Pitch Summary:
There is a structural shortage of housing in the USA. Higher mortgage rates reduce the supply of existing home supply as homeowners are locked into low-rate mortgages. Homebuilders can buy-down the mortgage to a lower rate and accept a lower, yet still healthy margin on the home sale. BLDR is a manufacturer and supplier of building materials with a focus on residential construction. Historically this business was cyclical with minimal pricing power as the primary products sold were lumber and other non-value-add housing materials. Since the GFC, BLDR has focused on growing their value-add business that is now 40%+ of the topline. The company has modest leverage and has been using their abundant free-cash-flow to buy over 45% of their stock in the last 33 months. In Q2 BLDR continued to experience a slower homebuilding market but continued to produce a healthy amount of free-cash-flow which they used to buy back stock. Given the slowdown, management reduced their 2025 outlook from generating $800MM-$1.2BB in cash to $800MM-$1BB in cash or a 6-8% FCF yield in a trough year. Their leverage has ticked up because of the core business slowing and I imagine they will focus on using some of their cash to reduce their debt going forward. The company has sustained higher gross margins as they have gained scale. I estimate normalized free-cash-flow per share to be $10-$15 per year implying a free-cash-flow yield of 9-13% with no growth priced in. The reality is due to the housing shortage coupled with acquisitions from smaller competitors; there is a long-term tailwind providing growth. Additionally local governments are beginning to loosen red tape for home construction which should help.

BSD Analysis:
BLDR remains a dominant force in building products distribution, with scale advantages, pricing power, and a digital platform that continues to pull share from smaller competitors. Margins remain elevated despite softer housing starts, reflecting disciplined operations and strong value-added product mix. Structural underbuilding in U.S. housing creates a multi-year demand runway. Despite a strong multi-year run, valuation remains undemanding relative to BLDR’s cash-generation profile. As volumes normalize, operating leverage should push earnings meaningfully higher.

Pitch Summary:
Jet2 is a structurally advantaged UK leisure travel operator combining a low-cost airline with the country's largest packaged holiday business, creating a vertically integrated model with superior economics and customer stickiness. Its refusal to use customer deposits to fund operations sets it apart from peers and has reinforced its reputation for reliability—especially evident during COVID, when Jet2 refunded customers immediately while competitors delayed. The company is growing capacity through new, fuel-efficient A321neo aircraft negotiated pre-inflation, enabling margin expansion and lower unit costs as seats per aircraft rise from 189 to 244. Jet2 has delivered long-term revenue and profit growth far above industry averages, driven by brand loyalty, operational discipline, and an increasingly opaque pricing advantage in packaged holidays. Its balance sheet strength is exceptional, with over £600m in true net cash despite heavy aircraft capex, due to strong FCF, high ROE, and positive working-capital float dynamics. Management is aggressively repurchasing shares, retiring 0.05–0.2% of the float *per day* and signaling sustained buyback intensity at today's valuation. With top-line growth likely to run ~10% annually and EPS compounding >20%, the market is deeply underpricing Jet2’s multiyear earnings power.

BSD Analysis:
Jet2 represents a rare combination of deep value, structural growth, and capital allocation excellence in a sector normally characterized by weak balance sheets and volatile profitability. Its vertically integrated model allows it to capture margin from both flights and holiday packages while insulating itself from pure airline price competition, as only half its seats must compete directly with low-cost carriers. The new aircraft order—secured during the COVID downturn—provides multi-year cost advantages not replicable by competitors constrained by Airbus/Boeing delivery backlogs. Jet2 generates outsized returns on equity thanks to its asset-light holiday business, significant customer float, and disciplined cost control, giving it airline-like growth without airline-typical fragility. Despite this, the stock trades at barely 6× earnings with ~20% of its market cap in net cash, allowing buybacks to materially shrink the share count over the next few years. Industry risks such as overcapacity, UK consumer weakness, and external shocks (volcanoes, wars, strikes) remain real, but Jet2 historically thrives in such environments by gaining share as weaker operators retrench or fail. Given likely EPS of £3+ within 2–3 years and a justified 10–12× multiple, the upside case implies 100–180% returns without heroic assumptions, while downside is cushioned by cash, buybacks, and a deeply loyal customer base.

Pitch Summary:
Ambea is a leading Nordic elderly, disability, and social care provider with ~1,000 facilities across Sweden, Norway, Denmark, and Finland, positioned to benefit from persistent demographic and capacity-driven tailwinds. The company enjoys CPI-linked municipal funding, creating inflation-protected, recurring revenue with minimal sensitivity to macro volatility. Structural shortages of beds, staffing, and specialized care capacity across the Nordic region support durable mid- to high-single-digit organic growth for years to come. Management has demonstrated strong execution in scaling the business, integrating acquisitions, and building high-margin specialized care units that offer superior economics to standard elderly care. Recent regulatory shifts—especially in Denmark and Finland—are opening the door to greater private-sector participation, supporting both volume and pricing. Ambea also benefits from embedded competitive advantages, including long regulatory relationships, scale-driven procurement benefits, and strong quality compliance systems. With clear opportunities for mix improvement, continued M&A, and rising public reliance on private providers, Ambea appears positioned to compound both cash flow and earnings well into the next decade.

BSD Analysis:
Ambea operates in a structurally advantaged segment of the Nordic care ecosystem, where demographic pressures and chronic public-sector understaffing create sustained, non-cyclical demand for high-quality private operators. The company’s long regulatory relationships and proven compliance infrastructure serve as both a credibility moat and a practical barrier to entry, especially as municipalities increasingly demand transparent quality metrics and outcome-based contracting. Scale advantages in procurement, staffing systems, and digital care workflows further widen the gap versus smaller competitors, enabling Ambea to sustain margins even through wage inflation and shifting labor regulations. Importantly, the company still has meaningful mix-upside as higher-acuity, higher-reimbursement units grow faster than legacy eldercare beds, improving both revenue intensity and capital efficiency. Management has also demonstrated consistent discipline in tuck-in M&A, acquiring and integrating underperforming providers whose economics rapidly normalize under Ambea’s playbook. With public-sector reliance on private operators rising—driven by constrained budgets and escalating care needs—the regulatory environment is likely to become more favorable to scaled, compliant operators rather than less. Given improving mix, operational leverage, and attractive pipeline visibility, Ambea is positioned to compound earnings and free cash flow at an above-market rate well into the next decade.

Pitch Summary:
Novabay is a micro-cap pharma shell whose only meaningful asset is roughly $6–7M of cash, equating to ~5c per pro forma share once a massively dilutive preferred financing converts into ~120M new shares at a 5c strike. The stock has recently spiked on a retail-driven misunderstanding of an already-paid special dividend and short-squeeze dynamics, but the company has no operating business of value and has chosen dilution over liquidation. A controversial financier, David Lazar, is providing $6M in preferred capital via Series D/E securities that convert automatically following shareholder approval on Oct 16, taking his stake to ~95% of the fully diluted share count. Novabay has simultaneously filed a $200M mixed shelf, suggesting further equity issuance once the registration becomes effective, which will expand the float and remove the remaining squeeze mechanics. Pro forma for the financing, the company will have ~125.8M shares outstanding with ~5c/share in cash versus a current ~$1.20 stock price, implying >90% downside once the market prices in the dilution.

BSD Analysis:
Novabay represents a classic micro-cap capital-structure trap: a failed business with no viable operations, a history of value-destructive decisions, and a board opting for extreme dilution rather than an orderly wind-down, leaving common shareholders structurally impaired. While the recent squeeze created a misleading price signal, the upcoming Oct 16 shareholder vote is a near-certain trigger for the automatic conversion of Series D/E preferred into 120M common shares, taking fully diluted shares from ~6M to ~126M almost overnight. The simultaneous filing of a $200M shelf further telegraphs management’s intent to issue more equity, which will both collapse the float-driven squeeze premium and pressure the stock toward its PF cash value. The buyer of the preferred, David Lazar, has a track record of similar restructurings leaving legacy shareholders significantly diluted, making this setup highly asymmetric to the downside. In short, this is a liquidity illusion temporarily supported by technical dynamics, not fundamentals, and fair value is near cash-per-share—roughly 5 cents.

Pitch Summary:
Bioventus is a small-cap musculoskeletal medtech company whose core assets—a high-growth hyaluronic acid knee OA franchise led by DUROLANE, a recovering EXOGEN bone-healing ultrasound business, and a nascent but fast-growing ultrasonics and bone graft substitutes platform—are obscured by a messy history of bad acquisitions, reimbursement noise, and complex rebate accounting. After near-distress in 2022 from CartiHeal/Misonix/Bioness deals and HA reimbursement resets, a new CEO has refocused on organic growth, margin expansion, and deleveraging; DUROLANE is taking share and growing well above the HA market, EXOGEN has finally returned to growth after years of decline, and ultrasonics/BGS are compounding double digits with a razor–razor-blade model. Street models still bake in conservative low-single-digit sales CAGRs and sub-$140M 2027 EBITDA, while the author underwrites closer to $670M sales and ~$170M EBITDA with >50% FCF conversion, implying >130% upside to ~$15.50/share at today’s ~8x LTM EBITDA entry. With net leverage trending down from ~3x, guidance that looks achievable once 1H rebate/timing noise is behind them, and downside of ~20% in a bear case, BVS screens as a mispriced, improving cash-flow story in an out-of-favor small-cap healthcare bucket.

BSD Analysis:
The opportunity in Bioventus is driven less by a hidden asset and more by a behavioral and structural blind spot: small-cap healthcare has been battered, the company nearly blew itself up with over-levered M&A, and the HA reimbursement reset plus opaque rebate accounting trained investors to dismiss reported numbers as low quality. As a result, the market is anchoring on old scars and headline leverage while underweighting the clean underlying trend: DUROLANE consistently outgrowing peers, EXOGEN inflecting from multi-year declines, and ultrasonics/BGS building a higher-margin recurring base that supports operating leverage and rapid deleveraging. The Street’s skepticism about a back-half-weighted guide, combined with limited product-level disclosure, keeps expectations muted, yet management only needs mid-single-digit organic growth and modest mix-driven margin gains to hit their 2025–27 targets. If they simply execute on the current plan—no heroic M&A, just steady growth, margin discipline, and debt paydown—the equity can re-rate toward a more normal medtech multiple on higher EBITDA, producing >2x upside with what appears to be well-defined, earnings-driven downside.

Pitch Summary:
Wolfpack alleges that Datasection is secretly supplying advanced NVIDIA GPUs to Tencent, a U.S.-blacklisted Chinese military-affiliated firm, in violation of U.S. export controls. Tencent appears to be the company’s only meaningful datacenter customer, raising concentration and compliance risks. Datasection’s financing discussions allegedly collapsed with Japanese banks once the purported illegality became evident, forcing the company to rely on China-linked capital instead. Wolfpack concludes the entire business model is built on unlawful activity that could trigger swift regulatory intervention.

BSD Analysis:
Datasection faces severe geopolitical, regulatory, and operational risks that fundamentally undermine its business viability. Its alleged reliance on a single Chinese military-linked customer exposes the firm to extreme revenue concentration and potential international sanctions. The company’s attempts to obscure the customer relationship and financing sources suggest material governance and transparency weaknesses. If Wolfpack’s claims are accurate, Datasection may face legal consequences that could interrupt operations, impair assets, or eliminate its ability to access capital markets. Competitive positioning is further weakened by the company’s lack of diversified revenue streams or defensible technology. Overall, Datasection’s risk profile is deeply asymmetric to the downside given the severity of alleged export-control violations.

Pitch Summary:
Wolfpack Research’s report contends that Datasection’s supposed “large cloud customer” backing its GPU supercluster project is Tencent, a Chinese technology conglomerate blacklisted by the U.S. government for ties to the Chinese military. By allegedly using shell entities such as NowNaw Japan to funnel restricted NVIDIA GPUs into China, Datasection risks breaching both U.S. and Japanese export control frameworks, which prohibit the transfer of advanced semiconductors to Chinese defense-linked firms. The report cites insider testimony and industry chatter that Japanese financial institutions have refused involvement, viewing the project as legally indefensible. Datasection’s CEO, Norihiko Ishihara, is accused of concealing Tencent’s involvement from staff and regulators while seeking state subsidies. Such conduct exposes the company to severe legal, regulatory, and reputational fallout. Given its dependence on this single illicit customer, any enforcement action could erase the company’s revenues and destroy shareholder value.

BSD Analysis:
Datasection’s growth story appears to hinge on a single customer relationship that may violate U.S. export control laws and Japan’s national security policy. Wolfpack Research alleges the firm is secretly supplying restricted NVIDIA B200 GPUs to Tencent — a U.S.-blacklisted Chinese military-linked entity — using intermediaries like NowNaw Japan (NNJ) to disguise the true counterparty. The alleged $272 million GPU “supercluster” project would represent a direct breach of U.S. export restrictions and undermine Japan’s geopolitical alignment with Western allies. Evidence from industry sources suggests Datasection misled investors, employees, and financiers about the identity of its sole datacenter client while pursuing government subsidies to fund an illegal operation. Japanese banks have reportedly refused financing, forcing the company toward China-linked capital sources and heightening regulatory exposure. If verified, the allegations could trigger criminal investigations, export bans, and the collapse of its core business model reliant on Tencent.

Pitch Summary:
Wolfpack Research’s report contends that Datasection’s supposed “large cloud customer” backing its GPU supercluster project is Tencent, a Chinese technology conglomerate blacklisted by the U.S. government for ties to the Chinese military. By allegedly using shell entities such as NowNaw Japan to funnel restricted NVIDIA GPUs into China, Datasection risks breaching both U.S. and Japanese export control frameworks, which prohibit the transfer of advanced semiconductors to Chinese defense-linked firms. The report cites insider testimony and industry chatter that Japanese financial institutions have refused involvement, viewing the project as legally indefensible. Datasection’s CEO, Norihiko Ishihara, is accused of concealing Tencent’s involvement from staff and regulators while seeking state subsidies. Such conduct exposes the company to severe legal, regulatory, and reputational fallout. Given its dependence on this single illicit customer, any enforcement action could erase the company’s revenues and destroy shareholder value.

BSD Analysis:
Datasection’s growth story appears to hinge on a single customer relationship that may violate U.S. export control laws and Japan’s national security policy. Wolfpack Research alleges the firm is secretly supplying restricted NVIDIA B200 GPUs to Tencent — a U.S.-blacklisted Chinese military-linked entity — using intermediaries like NowNaw Japan (NNJ) to disguise the true counterparty. The alleged $272 million GPU “supercluster” project would represent a direct breach of U.S. export restrictions and undermine Japan’s geopolitical alignment with Western allies. Evidence from industry sources suggests Datasection misled investors, employees, and financiers about the identity of its sole datacenter client while pursuing government subsidies to fund an illegal operation. Japanese banks have reportedly refused financing, forcing the company toward China-linked capital sources and heightening regulatory exposure. If verified, the allegations could trigger criminal investigations, export bans, and the collapse of its core business model reliant on Tencent.